Prevalence and Predictors of Neurocognitive Impairment in Ethiopian Population Living with HIV

Mohammed Salahuddin,1,2 Md Dilshad Manzar,3 Hamid Yimam Hassen,4,5 Aleem Unissa,6 Unaise Abdul Hameed,7 David Warren Spence,8 Seithikurippu R Pandi-Perumal9 1Department of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi University (Mizan Campus), Mizan, Ethiopia; 2Pharmacology Division...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Salahuddin M, Manzar MD, Hassen HY, Unissa A, Abdul Hameed U, Spence DW, Pandi-Perumal SR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	cart hiv ihds africa dementia ethiopia recreational drugs. Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/bb2bae65a5b34906b7fe0a36855af4d3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bb2bae65a5b34906b7fe0a36855af4d3
record_format	dspace
spelling	oai:doaj.org-article:bb2bae65a5b34906b7fe0a36855af4d32021-12-02T11:35:33ZPrevalence and Predictors of Neurocognitive Impairment in Ethiopian Population Living with HIV1179-1373https://doaj.org/article/bb2bae65a5b34906b7fe0a36855af4d32020-10-01T00:00:00Zhttps://www.dovepress.com/prevalence-and-predictors-of-neurocognitive-impairment-in-ethiopian-po-peer-reviewed-article-HIVhttps://doaj.org/toc/1179-1373Mohammed Salahuddin,1,2 Md Dilshad Manzar,3 Hamid Yimam Hassen,4,5 Aleem Unissa,6 Unaise Abdul Hameed,7 David Warren Spence,8 Seithikurippu R Pandi-Perumal9 1Department of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi University (Mizan Campus), Mizan, Ethiopia; 2Pharmacology Division, Department of BioMolecular Sciences, University of Mississippi, Oxford, Mississippi, USA; 3Department of Nursing, College of Applied Medical Sciences, Majmaah University, Al Majmaah 11952, Saudi Arabia; 4Department of Public Health, College of Health Sciences, Mizan Tepi University, (Mizan Campus), Mizan, Ethiopia; 5Department of Primary and Interdisciplinary Care, College of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; 6Malla Reddy College of Pharmacy, Hyderabad, Telangana, India; 7Department of Physiotherapy, Faculty of Medicine, Nursing and Health Sciences, Monash University, Australia; 8Independent Researcher, Toronto, ON M6K 2B4, Canada; 9Somnogen Canada Inc, Toronto, ON, CanadaCorrespondence: Mohammed Salahuddin Department of BioMolecular SciencesUniversity of Mississippi, School of Pharmacy, 331 Faser Hall, P.O. Box 1848, University, MS 38677-1848 Tel +1 662-609-3011Email smohamme@go.olemiss.eduBackground: Modern antiretroviral therapy has extended the life expectancies of people living with HIV; however, the prevention and treatment of their associated neurocognitive decline have remained a challenge. Consequently, it is desirable to investigate the prevalence and predictors of neurocognitive impairment to help in targeted screening and disease prevention.Materials and Methods: Two hundred and forty-four people living with HIV were interviewed in a study using a cross-sectional design and the International HIV Dementia Scale (IHDS). Additionally, the sociodemographic, clinical, and psychosocial characteristics of the patients were recorded. Chi-square and binary logistic regression analysis were used to determine the level of significance among the independent risk factors and probable neurocognitive impairment.Results: The point prevalence of neurocognitive impairment was found to be 39.3%. Participants’ characteristics of being older than 40 years (AOR= 2.81 (95% CI; 1.11– 7.15)), having a history of recreational drug use (AOR= 13.67 (95% CI; 6.42– 29.13)), and being non-compliant with prescribed medications (AOR= 2.99 (95% CI; 1.01– 8.87)) were independent risk factors for neurocognitive impairment.Conclusion: The identification of predictors, in the Ethiopian people living with HIV, may help in the targeted screening of vulnerable groups during cART follow-up visits. This may greatly help in strategizing and implementation of the prevention program, more so, because (i) HIV-associated neurocognitive impairment is an asymptomatic condition for considerable durations, and (ii) clinical trials on neurocognitive impairment therapies have been unsuccessful.Keywords: cART, HIV, IHDS, Africa, dementia, Ethiopia, recreational drugsSalahuddin MManzar MDHassen HYUnissa AAbdul Hameed USpence DWPandi-Perumal SRDove Medical Pressarticlecarthivihdsafricadementiaethiopiarecreational drugs.Immunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol Volume 12, Pp 559-572 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	cart hiv ihds africa dementia ethiopia recreational drugs. Immunologic diseases. Allergy RC581-607
spellingShingle	cart hiv ihds africa dementia ethiopia recreational drugs. Immunologic diseases. Allergy RC581-607 Salahuddin M Manzar MD Hassen HY Unissa A Abdul Hameed U Spence DW Pandi-Perumal SR Prevalence and Predictors of Neurocognitive Impairment in Ethiopian Population Living with HIV
description	Mohammed Salahuddin,1,2 Md Dilshad Manzar,3 Hamid Yimam Hassen,4,5 Aleem Unissa,6 Unaise Abdul Hameed,7 David Warren Spence,8 Seithikurippu R Pandi-Perumal9 1Department of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi University (Mizan Campus), Mizan, Ethiopia; 2Pharmacology Division, Department of BioMolecular Sciences, University of Mississippi, Oxford, Mississippi, USA; 3Department of Nursing, College of Applied Medical Sciences, Majmaah University, Al Majmaah 11952, Saudi Arabia; 4Department of Public Health, College of Health Sciences, Mizan Tepi University, (Mizan Campus), Mizan, Ethiopia; 5Department of Primary and Interdisciplinary Care, College of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; 6Malla Reddy College of Pharmacy, Hyderabad, Telangana, India; 7Department of Physiotherapy, Faculty of Medicine, Nursing and Health Sciences, Monash University, Australia; 8Independent Researcher, Toronto, ON M6K 2B4, Canada; 9Somnogen Canada Inc, Toronto, ON, CanadaCorrespondence: Mohammed Salahuddin Department of BioMolecular SciencesUniversity of Mississippi, School of Pharmacy, 331 Faser Hall, P.O. Box 1848, University, MS 38677-1848 Tel +1 662-609-3011Email smohamme@go.olemiss.eduBackground: Modern antiretroviral therapy has extended the life expectancies of people living with HIV; however, the prevention and treatment of their associated neurocognitive decline have remained a challenge. Consequently, it is desirable to investigate the prevalence and predictors of neurocognitive impairment to help in targeted screening and disease prevention.Materials and Methods: Two hundred and forty-four people living with HIV were interviewed in a study using a cross-sectional design and the International HIV Dementia Scale (IHDS). Additionally, the sociodemographic, clinical, and psychosocial characteristics of the patients were recorded. Chi-square and binary logistic regression analysis were used to determine the level of significance among the independent risk factors and probable neurocognitive impairment.Results: The point prevalence of neurocognitive impairment was found to be 39.3%. Participants’ characteristics of being older than 40 years (AOR= 2.81 (95% CI; 1.11– 7.15)), having a history of recreational drug use (AOR= 13.67 (95% CI; 6.42– 29.13)), and being non-compliant with prescribed medications (AOR= 2.99 (95% CI; 1.01– 8.87)) were independent risk factors for neurocognitive impairment.Conclusion: The identification of predictors, in the Ethiopian people living with HIV, may help in the targeted screening of vulnerable groups during cART follow-up visits. This may greatly help in strategizing and implementation of the prevention program, more so, because (i) HIV-associated neurocognitive impairment is an asymptomatic condition for considerable durations, and (ii) clinical trials on neurocognitive impairment therapies have been unsuccessful.Keywords: cART, HIV, IHDS, Africa, dementia, Ethiopia, recreational drugs
format	article
author	Salahuddin M Manzar MD Hassen HY Unissa A Abdul Hameed U Spence DW Pandi-Perumal SR
author_facet	Salahuddin M Manzar MD Hassen HY Unissa A Abdul Hameed U Spence DW Pandi-Perumal SR
author_sort	Salahuddin M
title	Prevalence and Predictors of Neurocognitive Impairment in Ethiopian Population Living with HIV
title_short	Prevalence and Predictors of Neurocognitive Impairment in Ethiopian Population Living with HIV
title_full	Prevalence and Predictors of Neurocognitive Impairment in Ethiopian Population Living with HIV
title_fullStr	Prevalence and Predictors of Neurocognitive Impairment in Ethiopian Population Living with HIV
title_full_unstemmed	Prevalence and Predictors of Neurocognitive Impairment in Ethiopian Population Living with HIV
title_sort	prevalence and predictors of neurocognitive impairment in ethiopian population living with hiv
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/bb2bae65a5b34906b7fe0a36855af4d3
work_keys_str_mv	AT salahuddinm prevalenceandpredictorsofneurocognitiveimpairmentinethiopianpopulationlivingwithhiv AT manzarmd prevalenceandpredictorsofneurocognitiveimpairmentinethiopianpopulationlivingwithhiv AT hassenhy prevalenceandpredictorsofneurocognitiveimpairmentinethiopianpopulationlivingwithhiv AT unissaa prevalenceandpredictorsofneurocognitiveimpairmentinethiopianpopulationlivingwithhiv AT abdulhameedu prevalenceandpredictorsofneurocognitiveimpairmentinethiopianpopulationlivingwithhiv AT spencedw prevalenceandpredictorsofneurocognitiveimpairmentinethiopianpopulationlivingwithhiv AT pandiperumalsr prevalenceandpredictorsofneurocognitiveimpairmentinethiopianpopulationlivingwithhiv
_version_	1718395842666168320

Prevalence and Predictors of Neurocognitive Impairment in Ethiopian Population Living with HIV

Ejemplares similares